Yesterday, Feb. 24, 2016, 77 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $250.66 to $7,618,160.00.

Highlighted Stocks Traded by Insiders:

Duke Energy Corporation (DUK) - FREE Research Report

Yates Lloyd M, who is EVPMkt Solutions;PresCarolinas at Duke Energy Corporation, sold 2,000 shares at $74.65 on Feb. 24, 2016. Following this transaction, the EVPMkt Solutions;PresCarolinas owned 38,240 shares meaning that the stake was reduced by 4.97% with the 2,000-share transaction.

Savoy Brian D, who is SVP,Controller,Chief Acct Off at Duke Energy Corporation, sold 100 shares at $75.10 on Feb. 24, 2016. Following this transaction, the SVP,Controller,Chief Acct Off owned 2,111 shares meaning that the stake was reduced by 4.52% with the 100-share transaction.

The shares most recently traded at $75.57, up $0.47, or 0.62% since the insider transaction. Historical insider transactions for Duke Energy Corporation go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 3,627
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 3,627

The average volume for Duke Energy Corporation has been 3.7 million shares per day over the past 30 days. Duke Energy Corporation has a market cap of $51.5 billion and is part of the utilities sector and utilities industry. Shares are up 4.99% year-to-date as of the close of trading on Wednesday.

Duke Energy Corporation, together with its subsidiaries, operates as an energy company in the United States and Latin America. It operates through three segments: Regulated Utilities, International Energy, and Commercial Power. The stock currently has a dividend yield of 4.41%. The company has a P/E ratio of 18.6. Currently, there are 6 analysts who rate Duke Energy Corporation a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DUK - FREE

TheStreet Quant Ratings

rates Duke Energy Corporation as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Duke Energy Corporation Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

State Auto Financial (STFC) - FREE Research Report

Larocco Michael, who is President, CEO at State Auto Financial, bought 1,819 shares at $21.25 on Feb. 24, 2016. Following this transaction, the President, CEO owned 19,051 shares meaning that the stake was boosted by 10.56% with the 1,819-share transaction.

The shares most recently traded at $21.26, up $0.01, or 0.05% since the insider transaction. Historical insider transactions for State Auto Financial go as follows:

  • 4-Week # shares bought: 1,643
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 1,643
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 1,643
  • 24-Week # shares sold: 10,000

The average volume for State Auto Financial has been 36,600 shares per day over the past 30 days. State Auto Financial has a market cap of $879.6 million and is part of the financial sector and insurance industry. Shares are up 4.27% year-to-date as of the close of trading on Wednesday.

State Auto Financial Corporation, through its subsidiaries, engages in writing personal, business, and specialty insurance products. It operates through four segments: Personal insurance, Business insurance, Specialty insurance, and Investment operations. The stock currently has a dividend yield of 1.88%. The company has a P/E ratio of 25.0. Currently, there is 1 analyst who rates State Auto Financial a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STFC - FREE

TheStreet Quant Ratings

rates State Auto Financial as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

State Auto Financial Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regulus Therapeutics (RGLS) - FREE Research Report

Alnylam Pharmaceuticals, Inc., who is 10% Owner at Regulus Therapeutics, sold 1.0 million shares at $7.18 on Feb. 24, 2016. Following this transaction, the 10% Owner owned 4.9 million shares meaning that the stake was reduced by 16.96% with the 1.0 million-share transaction.

The shares most recently traded at $6.46, down $0.72, or 11.15% since the insider transaction. Historical insider transactions for Regulus Therapeutics go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 13,248
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 343,133
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 343,133

The average volume for Regulus Therapeutics has been 717,100 shares per day over the past 30 days. Regulus Therapeutics has a market cap of $366.9 million and is part of the health care sector and drugs industry. Shares are down 22.02% year-to-date as of the close of trading on Wednesday.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. Currently, there are 5 analysts who rate Regulus Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RGLS - FREE

TheStreet Quant Ratings

rates Regulus Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Regulus Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.